Amarillo Biosciences to Explore Low-Dose Oral Interferon Therapeutics in China as a Line of Defense Against Coronavirus and Other Viral Indications
February 13, 2020 12:56 ET
|
Amarillo Biosciences, Inc.
Amarillo, TX, Feb. 13, 2020 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Amarillo Biosciences, Inc. (“ABI” or the “Company”), (AMAR), a diversified healthcare company, today announced that its China...
Amarillo Biosciences and Xiamen Weiyang Pharmaceutical Sign Term Sheet Outlining China Licensing and Royalty Agreement
July 29, 2019 10:54 ET
|
Amarillo Biosciences, Inc.
Amarillo, TX, July 29, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Amarillo Biosciences, Inc. (“ABI” or the “Company”), (OTCBB: AMAR), a diversified healthcare company, today announced that it has...